Ovarian Cancer Research Alliance

New York, New York, 10122-1491 United States

Mission Statement

OCRA is the leading organization in the world fighting ovarian cancer on all fronts while supporting patients and their families.

About This Cause

Ovarian Cancer Research Alliance (OCRA) is the largest global organization dedicated to fighting ovarian cancer. We advance research to prevent, treat and defeat ovarian cancer. We support women and their families before, during and beyond diagnosis. And we work with all levels of government to ensure ovarian cancer is a priority. RESEARCH OCRA is the largest non-government funder of ovarian cancer research and has the longest track record of impact. Since 1998, we have invested more than $110 million to jumpstart promising research and hasten desperately needed breakthroughs. Every day, OCRA-funded scientists are finding new ways to treat, prevent and ultimately cure ovarian cancer. PATIENT SUPPORT Our programs help people navigate an overwhelming diagnosis, supporting patients and their families when and where they need it most. Our Woman to Woman peer support program pairs newly diagnosed patients with survivors who provide hope and insight, and our Ovarian Cancer National Conference brings survivors together to share knowledge and build community. ADVOCACY OCRA is the voice for the ovarian cancer community, working with legislators to ensure federal ovarian cancer research and education, patient safety, and access to high-quality care re protected on Capitol Hill. We also change the way future healthcare professionals recognize ovarian cancer through our Survivors Teaching Students program. OCRA is the world's leader in fighting ovarian cancer. Through your generous support we can continue funding cures, advocating for patients, and supporting survivors. Together, we are uniting to defeat ovarian cancer.

Ovarian Cancer Research Alliance
14 Pennsylvania Plaza Ste 2110
New York, New York 10122-1491
United States
Phone 2122681002
Twitter @OCRA
Unique Identifier 133806788